Clinical Pharmacological Considerations on CAR-T Cell Therapy for Cancer

  title={Clinical Pharmacological Considerations on CAR-T Cell Therapy for Cancer},
  author={Zhan Wang},
During the past 70 years, cancer therapy has undergone extensive growth from pharmacotherapy toward targeted therapy, poised upon the considerations of efficacy and safety of clinically applied drugs [1]. The strategy behind this growth was to optimize the structures of the drugs, from synthesized chemical entities to biologics, to enhance the specificity between drugs and disease targets for better potency, and yet to minimize adverse effects to healthy cells. From the 2000s, a better… Expand

Topics from this paper

Convergence of Cell Pharmacology and Drug Delivery
A perspective on the development of an ex vivo mesenchymal stromal therapeutic using a PK/ PD framework is presented and examples of general cell engineering techniques that implicitly influence the PK/PD curve by genetically modifying cells to regulate their in vivo duration, biodistribution, and activity are presented. Expand
Considerations for setting occupational exposure limits for novel pharmaceutical modalities
This manuscript reviews the available literature for emerging modalities and provides considerations for occupational health and safety-oriented hazard identification and risk assessments to enable timely, consistent and well-informed hazard identification, hazard communication and risk-management decisions. Expand
Clinical Pharmacological Considerations on CAR-T Cell Therapy for Cancer
The aim of adoptive cell therapy (ACT) is to genetically engineer the collected patients’ T-cells to express cell surface receptor(s) specific to cancer targets and subsequently to administer those modified CAR-T cells back into the same patient. Expand


Clinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacokinetics and antitumor effects.
The current knowledge on the clinical pharmacology aspects of what is anticipated to be a brand new class of biopharmaceuticals to join the therapeutic armamentarium of cancer doctors are summarized. Expand
Biology and clinical application of CAR T cells for B cell malignancies
An overview of recent pre-clinical advances in CAR design argues favorably for the advancement of CAR therapy to tackle other hematological malignancies as well as solid tumors. Expand
Chimeric antigen receptor modified T cell therapy for B cell malignancies
  • C. Turtle
  • Biology, Medicine
  • International Journal of Hematology
  • 2013
Administration of CD19-specific CAR-modified T cells that target B cell non-Hodgkin lymphomas and leukemia has been remarkably effective in recent clinical trials, energizing the field and stimulating new efforts to identify the critical parameters of CAR design and T cell engineering that are necessary for effective cancer therapy. Expand
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
The concept of chimeric antigen receptor gene‐modified T cells is explained, the extant results in hematologic malignancies are described, and the outlook on where this modality is likely to head in the near future is shared. Expand
Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
The findings support the clinical evaluation of R OR1 CAR-T cells for ROR1+ malignancies and demonstrate the utility of nonhuman primates for evaluating the safety of immunotherapy with engineered T cells specific for tumor-associated molecules that are homologous between humans and nonhuman chimpanzees. Expand
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
It is speculated that the large number of administered cells localized to the lung immediately following infusion and were triggered to release cytokine by the recognition of low levels of ERBB2 on lung epithelial cells, consistent with a cytokine storm. Expand
Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape
Comparisons between studies have been made in an effort to identify critical factors that govern outcomes of CAR-T cell immunotherapy, and patterns identified from analyses of correlative laboratory data and clinical outcomes are emerging and beginning to guide the field. Expand
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes
E engineered CAR-T cells to express HPSE and showed their improved capacity to degrade the ECM, which promoted tumor T cell infiltration and antitumor activity, and the use of this strategy may enhance the activity of CAR- T cells in individuals with stroma-rich solid tumors. Expand
4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors
It is shown that tonic CAR CD3-ζ phosphorylation, triggered by antigen-independent clustering of CAR single-chain variable fragments, can induce early exhaustion of CAR T cells that limits antitumor efficacy, and that CD28 costimulation augments, whereas 4-1BB costimulations reduces, exhaustion induced by persistent CAR signaling. Expand
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL and was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed. Expand